Hexagon Capital Partners’s ImmunityBio IBRX Stock Holding History

Hexagon Capital Partners’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,000	Closed	-$3.01K	–	834
2025 Q1	$3.01K	Buy	+1,000	New	+$3.03K	﹤0.01%	1299

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return

Hexagon Capital Partners's IBRX Position: Q2 2025 in Review

Hexagon Capital Partners sold out of ImmunityBio (IBRX) in Q2 2025, closing a stake of 1,000 shares — an estimated $3.01K sold.

Hexagon Capital Partners first reported a position in IBRX in Q1 2025 and held it in 1 quarter. The position peaked at $3.01K in Q1 2025. 241 funds tracked by Wall St. Rank hold IBRX as of Q2 2025.

Hexagon Capital Partners reported no remaining ImmunityBio position as of Q2 2025 after selling out during the quarter.
Hexagon Capital Partners sold 1,000 ImmunityBio shares in Q2 2025, an estimated $3.01K.
Hexagon Capital Partners first reported a position in ImmunityBio in Q1 2025 and held it in 1 quarter.
Hexagon Capital Partners's ImmunityBio position peaked at $3.01K in Q1 2025.
241 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.